Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMRSG31)

Drug Name	BCX-3408 DMRSG31
Synonyms	ULODESINE; 548486-59-5; UNII-JNG8L9460Y; JNG8L9460Y; CHEMBL269864; DADMe-immucillin H; Ulodesine [USAN:INN]; Ulodesine (USAN); DADMe-ImmH,7; 1n3i; AC1L9KNW; 7-[[(3R,4R)-3-(hydroxymethyl)-4-oxidanyl-pyrrolidin-1-ium-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one; R-3421; SCHEMBL474735; SCHEMBL16320802; CTK5A2657; BDBM22109; DTXSID00203332; AKOS030554378; DB12353; SB17254; D10431; 4H-Pyrrolo[3,2-d]pyrimidin-4-one,1,5-dihydro-7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-pyrrolidinyl]methyl]-; BCX-4208; Ulodesine
Drug Type	Small molecular drug
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

3 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Autoimmune diabetes	DISW6UF1	5A10	Phase 2	[1]
Plaque psoriasis	DISQX1LF	EA90.0	Phase 2	[1]
Gout	DISHC0U7	FA25	Phase 2	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01407874) A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency. U.S. National Institutes of Health.